Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005028 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 4
- Study locations
NCT00005028: Completed Phase 2 study of Prostate Cancer, sponsored by University of Maryland, Baltimore.
NCT00005028 is a Phase 2 study of Prostate Cancer that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 46 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005028, a Phase 2 study of Prostate Cancer, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 4
- Study locations
Study Summary
Phase II trial to study the effectiveness of combining paclitaxel and bryostatin 1 in treating patients who have metastatic prostate cancer that has not responded to hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Conditions Studied
Interventions
- DRUG paclitaxel
- DRUG bryostatin 1
Study Locations (4)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- Wellspan Health - York Cancer Center - York
Maryland
- Greater Baltimore Medical Center and Cancer Center - Baltimore
North Carolina
- Comprehensive Cancer Center at Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2000-05 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
What the finished NCT00005028 record still lists
NCT00005028 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.
NCT00005028 reports a single indexed study location in Pennsylvania, Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00005028 about?
NCT00005028 is a clinical study titled "Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer". Phase II trial to study the effectiveness of combining paclitaxel and bryostatin 1 in treating patients who have metastatic prostate cancer that has not responded to hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combinin...
What is the current status of trial NCT00005028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2000-05. Estimated completion is 2006-07.
What conditions does trial NCT00005028 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00005028?
The interventions under investigation include: paclitaxel (DRUG), bryostatin 1 (DRUG).
Who is sponsoring clinical trial NCT00005028?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005028 being conducted?
This trial has 4 study locations across Maryland, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00005028's enrollment target sits among peer trials
46 504th of 735 higher than 231 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia